The effect of butyl phthalide in the treatment of acute cerebral infarction and its influence on serum MCP-1 and vWF / 中国基层医药

ABSTRACT

Objective To study the relationship of serum monocyte chemotactic factor 1 ( MCP-1) and von willebrand factor (vWF) in patients with acute cerebral infarction and the therapeutic effect of butyl phthalide soft capsule.Methods As the research subjects,160 patients of acute cerebral infarction were randomly divided into two groups,80 cases in the observation group,80 cases in the control group.80 cases of healthy physical examination in our hospital were enrolled as the healthy group.The treatment control group was given conventional treatment,treat-ment observation group on the basis of conventional treatment combined with butyl phthalide soft capsule,0.2g orally, three times a day.They were treated for three months.Serum MCP-1 and vWF were detected.Results Before treat-ment,serum MCP-1 and vWF in the observation group and the control group were significantly higher than those in the healthy group(P<0.01).Before treatment,the serum MCP-1 was (480.2 ±34.2)pg/mL,vWF was (2.70 ± 0.45)μg/L,serum MCP-1 and vWF was positively correlated(r=0.286 2,P<0.05).The two groups after treat-ment serum MCP-1 and vWF were significantly decreased,and compared with the control group,the decrease of ser-um vWF and MCP-1 in the observation group was more obvious(P<0.05).Conclusion Serum MCP-1 and vWF has obvious relationship in acute cerebral infarction,butyl phthalide soft capsule can significantly lower the serum con-centration.